ACTR-30. PHASE 1B/2 STUDY TO ASSESS THE CLINICAL EFFECTS OF PAMIPARIB (BGB-290) IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY GLIOBLASTOMA (GBM)

DNA damage caused by TMZ or RT sensitizes tumors to PARP inhibitors, especially in highly replicating tumors (eg, GBM). Pamiparib is a selective PARP1/2 inhibitor with potent PARP trapping that can cross the blood-brain barrier and has shown synergistic cytotoxicity with TMZ in nonclinical experimen...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Shih, Kent, Schiff, David, Kim, Lyndon, Battiste, James, Campian, Jian, Puduvalli, Vinay, Wen, Patrick, Cloughesy, Timothy, van den Bent, Martin, Pirzkall, Andrea, Wood, Katie, Wei, Rachel, Du, Bing, Mu, Song, Ramakrishnan, Vanitha, Walbert, Tobias
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2018
Soggetti:
Abstracts
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216180/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.063
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi